![Orion Corporation](/common/images/company/BIT_1ORNBV.png)
Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint ORION...
Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic...
Orion is developing the Finnish life science industry in a unique collaboration project ORION CORPORATION PRESS RELEASE 03 June 2024 at 09.30 EEST Orion is developing the Finnish life...
Orion Corporation: Change in Orion Group Executive Management Board as of 31 May 2025 ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD / MANAGEMENT / AUDITORS7 May 2024 at 08.30 EEST...
Orion Corporation: Managers’ transactions – Maziar Mike Doustdar ORION CORPORATION MANAGERS’ TRANSACTIONS 6 MAY 2024 at 12.00 EEST Orion Corporation: Managers’ transactions – Maziar...
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) ORION CORPORATION STOCK EXCHANGE RELEASE – MAJOR SHAREHOLDER ANNOUNCEMENTS26 APRIL 2024...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 1.34 | 3.62456045442 | 36.97 | 38.31 | 36.97 | 15 | 37.41666667 | DE |
26 | -4.93 | -11.401480111 | 43.24 | 44.42 | 34.88 | 75 | 42.13334928 | DE |
52 | 1.38 | 3.73679935012 | 36.93 | 44.42 | 34.88 | 83 | 42.20589226 | DE |
156 | 1.38 | 3.73679935012 | 36.93 | 44.42 | 34.88 | 83 | 42.20589226 | DE |
260 | 1.38 | 3.73679935012 | 36.93 | 44.42 | 34.88 | 83 | 42.20589226 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.